Table 1.

Meta-analysis results of oncology trials that examined erythopoietin’s affect on disease progression in patients receiving chemotherapy

Study publication	Tumor type	No. of patients analyzed	Odds ratio (95%) for disease progression
Osterborg et al. 1996[34]	Hematologic	144	1.20 (0.60-2.40)
Littlewood et al. 2001[35]	Solid (non-hematologic)	375	0.64 (0.40-1.02)
Pronzato et al. 2010[36]	Breast	223	1.02 (0.46-2.26)
Vansteenkiste et al. 2002[37]	SCLC and NSCLC	314	0.58 (0.30-1.11)
Hedenus et al. 2003[38]	Hematologic	344	1.08 (0.66-1.76)
Vadhan-Raj et al. 2003[39]	Gastric and rectal	60	1.01 (0.35-2.94)
Chang et al. 2005[40]	Breast	354	0.82 (0.39-1.72)
Grote et al. 2005[41]	SCLC	224	0.85 (0.50-1.44)
Leyland-Jones et al. 2005[42]	Breast	939	0.84 (0.64-1.08)
Osterborg et al. 2005[43]	Hematologic	343	0.74 (0.44-1.25)
Witzig et al. 2005[44]	Mixed	344	1.20 (0.75-1.91)
Wilkinson et al. 2006[11]	Ovarian	181	7.47 (0.95-58.54)
Engert et al. 2007[45]	Hodgkin’s lymphoma	1303	0.86 (0.33-2.24)
Aapro et al. 2008[46]	Breast	463	1.07 (0.82-1.40)
Pirker et al. 2008[47]	SCLC	596	0.87 (0.52-1.46)
Strauss et al. 2008[48]	Cervical	74	0.87 (0.32-2.33)
Thomas et al. 2008[49]	Cervical	109	1.02 (0.48-2.15)